The world of sexually transmitted infections (STIs) is evolving, and not necessarily for the better. The latest warning comes from health officials who have observed a worrying trend – an increase in cases of gonorrhoea that are resistant to strong antibiotics like ceftriaxone. This isn’t just any rise; it’s a significant jump that has experts on high alert.
As per the United Kingdom Health Security Agency (UKHSA), the numbers paint a concerning picture. In 2025, there have been more instances of ceftriaxone-resistant gonorrhoea than throughout the entirety of last year. While overall gonorrhoea cases saw a 16% decrease in England in 2024 compared to the previous year, cases resistant to ceftriaxone are surfacing more frequently – with 14 recorded in the first five months of 2025 versus 13 in 2024.
What’s even more alarming is that six out of these 14 cases this year are classified as “extensively drug-resistant,
” meaning they show resistance not only to ceftriaxone but also to second-line treatment options. Ceftriaxone is considered a potent antibiotic and is typically the primary choice for treating gonorrhoea. When infections start shrugging off this powerful drug, it raises serious concerns among experts.
Most of these drug-resistant cases seem to have connections with travel to or from the Asia-Pacific region, where ceftriaxone resistance rates are notably high. Apart from this specific issue, England has also witnessed an uptick in early-stage syphilis diagnoses by 1.7% from 2023 to 2024. The broader spectrum including late-stage syphilis or complications arising from the infection increased by about five percent during the same period.
On another front, chlamydia cases saw a decline by about thirteen percent while new genital warts diagnoses dropped as well. However, there was also a notable decrease – approximately ten percent – in chlamydia tests conducted among women aged between fifteen and twenty-four through the National Chlamydia Screening Programme (NCSP).
Dr Hamish Mohammed, a consultant epidemiologist at UKHSA, emphasized how crucial it is to remain vigilant against STIs given their potential repercussions on one’s own health and that of their sexual partners. He stressed on regular testing even without symptoms saying, “If you’ve had condomless sex with new or casual partners – either in the UK or overseas – get tested for STIs and HIV at least yearly.”
In response to these challenges posed by antibiotic-resistant STIs like gonorrhoea, Professor Matt Phillips urged for proactive measures stating: “It is vital that clear steps are put in place to reverse these trends.” As President of the British Association for Sexual Health and HIV, he highlighted ongoing pressures faced by sexual health services and emphasized the need for strategic planning.
Professor Phillips further underlined how critical it is for sexual health services to be adequately equipped stating: “Only a joined-up ambitious national strategy can ensure that we are prepared not just for today’s sexual health challenges but those we know are coming.” These cautionary words shed light on an increasingly complex landscape where traditional treatments may no longer suffice.
In conclusion, staying informed about safe sexual practices and prioritizing regular screenings emerge as key strategies against antibiotic-resistant STIs like never before. It’s not just about personal well-being; it’s about safeguarding public health amidst evolving threats that demand proactive responses.
Leave feedback about this